Akeso Past Earnings Performance

Past criteria checks 0/6

Akeso has been growing earnings at an average annual rate of 40.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 80.1% per year.

Key information

40.4%

Earnings growth rate

53.4%

EPS growth rate

Biotechs Industry Growth	11.0%
Revenue growth rate	80.1%
Return on equity	-15.5%
Net Margin	-39.2%
Last Earnings Update	30 Jun 2024

Recent past performance updates

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Mar 25

Recent updates

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 30

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Jun 19

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Dec 28

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Nov 16

Is Akeso (HKG:9926) Using Too Much Debt?

Oct 02

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Jun 26

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

May 22

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Apr 11

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Mar 21

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Mar 02

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Aug 28

Revenue & Expenses Breakdown

How Akeso makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:9926 Revenue, expenses and earnings (CNY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	1,874	-735	1,164	1,274
31 Mar 24	3,200	646	1,127	1,264
31 Dec 23	4,526	2,028	1,090	1,254
30 Sep 23	4,439	2,008	1,071	1,278
30 Jun 23	4,351	1,987	1,052	1,302
31 Mar 23	2,595	409	902	1,313
31 Dec 22	838	-1,168	752	1,323
30 Sep 22	549	-1,224	672	1,239
30 Jun 22	260	-1,280	592	1,155
31 Mar 22	243	-1,178	508	1,139
31 Dec 21	226	-1,075	423	1,123
30 Sep 21	177	-1,002	324	1,107
30 Jun 21	129	-929	226	1,091
31 Mar 21	64	-983	240	930
31 Dec 20	0	-1,036	253	769
30 Sep 20	35	-870	197	597
30 Jun 20	71	-703	141	426
31 Mar 20	71	-492	98	367
31 Dec 19	71	-282	55	308
31 Dec 18	3	-142	20	161

Quality Earnings: 9926 is currently unprofitable.

Growing Profit Margin: 9926 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 9926 is unprofitable, but has reduced losses over the past 5 years at a rate of 40.4% per year.

Accelerating Growth: Unable to compare 9926's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9926 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.8%).

Return on Equity

High ROE: 9926 has a negative Return on Equity (-15.49%), as it is currently unprofitable.

Akeso Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Recent updates

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Is Akeso (HKG:9926) Using Too Much Debt?

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2023

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Now 24% undervalued

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile